Report cover image

Global Nimodipine Sustained Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 196 Pages
SKU # APRC20356385

Description

Summary

According to APO Research, The global Nimodipine Sustained Release Tablets market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Nimodipine Sustained Release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Nimodipine Sustained Release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Nimodipine Sustained Release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Nimodipine Sustained Release Tablets is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Nimodipine Sustained Release Tablets include Arbor Pharmaceuticals, Bayer Vital, Bionpharma, Heritage Pharmaceuticals, Pharmaceutics International, Sofgen Pharmaceuticals, Wuhan HITECK Biopharmaceutical, Sihuan Pharmaceutical and Jiangsu Kanion Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Nimodipine Sustained Release Tablets, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Nimodipine Sustained Release Tablets, also provides the sales of main regions and countries. Of the upcoming market potential for Nimodipine Sustained Release Tablets, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nimodipine Sustained Release Tablets sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nimodipine Sustained Release Tablets market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Nimodipine Sustained Release Tablets sales, projected growth trends, production technology, application and end-user industry.

Nimodipine Sustained Release Tablets Segment by Company

Arbor Pharmaceuticals
Bayer Vital
Bionpharma
Heritage Pharmaceuticals
Pharmaceutics International
Sofgen Pharmaceuticals
Wuhan HITECK Biopharmaceutical
Sihuan Pharmaceutical
Jiangsu Kanion Pharmaceutical
Qilu Pharmaceutical
Shandong Yunmen Pharmaceutical
Yabao Pharmaceutical Group
Nimodipine Sustained Release Tablets Segment by Type

30mg/Piece
60mg/Piece
Others
Nimodipine Sustained Release Tablets Segment by Application

Hospital
Pharmacy
Others
Nimodipine Sustained Release Tablets Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nimodipine Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nimodipine Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nimodipine Sustained Release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nimodipine Sustained Release Tablets market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nimodipine Sustained Release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nimodipine Sustained Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Nimodipine Sustained Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Nimodipine Sustained Release Tablets Market Size, 2020 VS 2024 VS 2031
1.3 Global Nimodipine Sustained Release Tablets Market Size Estimates and Forecasts (2020-2031)
1.4 Global Nimodipine Sustained Release Tablets Sales Estimates and Forecasts (2020-2031)
1.5 Global Nimodipine Sustained Release Tablets Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Nimodipine Sustained Release Tablets Market Dynamics
2.1 Nimodipine Sustained Release Tablets Industry Trends
2.2 Nimodipine Sustained Release Tablets Industry Drivers
2.3 Nimodipine Sustained Release Tablets Industry Opportunities and Challenges
2.4 Nimodipine Sustained Release Tablets Industry Restraints
3 Nimodipine Sustained Release Tablets Market by Manufacturers
3.1 Global Nimodipine Sustained Release Tablets Revenue by Manufacturers (2020-2025)
3.2 Global Nimodipine Sustained Release Tablets Sales by Manufacturers (2020-2025)
3.3 Global Nimodipine Sustained Release Tablets Average Sales Price by Manufacturers (2020-2025)
3.4 Global Nimodipine Sustained Release Tablets Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Nimodipine Sustained Release Tablets Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Nimodipine Sustained Release Tablets Manufacturers, Product Type & Application
3.7 Global Nimodipine Sustained Release Tablets Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Nimodipine Sustained Release Tablets Market CR5 and HHI
3.8.2 Global Top 5 and 10 Nimodipine Sustained Release Tablets Players Market Share by Revenue in 2024
3.8.3 2024 Nimodipine Sustained Release Tablets Tier 1, Tier 2, and Tier 3
4 Nimodipine Sustained Release Tablets Market by Type
4.1 Nimodipine Sustained Release Tablets Type Introduction
4.1.1 30mg/Piece
4.1.2 60mg/Piece
4.1.3 Others
4.2 Global Nimodipine Sustained Release Tablets Sales by Type
4.2.1 Global Nimodipine Sustained Release Tablets Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Nimodipine Sustained Release Tablets Sales by Type (2020-2031)
4.2.3 Global Nimodipine Sustained Release Tablets Sales Market Share by Type (2020-2031)
4.3 Global Nimodipine Sustained Release Tablets Revenue by Type
4.3.1 Global Nimodipine Sustained Release Tablets Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Nimodipine Sustained Release Tablets Revenue by Type (2020-2031)
4.3.3 Global Nimodipine Sustained Release Tablets Revenue Market Share by Type (2020-2031)
5 Nimodipine Sustained Release Tablets Market by Application
5.1 Nimodipine Sustained Release Tablets Application Introduction
5.1.1 Hospital
5.1.2 Pharmacy
5.1.3 Others
5.2 Global Nimodipine Sustained Release Tablets Sales by Application
5.2.1 Global Nimodipine Sustained Release Tablets Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Nimodipine Sustained Release Tablets Sales by Application (2020-2031)
5.2.3 Global Nimodipine Sustained Release Tablets Sales Market Share by Application (2020-2031)
5.3 Global Nimodipine Sustained Release Tablets Revenue by Application
5.3.1 Global Nimodipine Sustained Release Tablets Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Nimodipine Sustained Release Tablets Revenue by Application (2020-2031)
5.3.3 Global Nimodipine Sustained Release Tablets Revenue Market Share by Application (2020-2031)
6 Global Nimodipine Sustained Release Tablets Sales by Region
6.1 Global Nimodipine Sustained Release Tablets Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Nimodipine Sustained Release Tablets Sales by Region (2020-2031)
6.2.1 Global Nimodipine Sustained Release Tablets Sales by Region (2020-2025)
6.2.2 Global Nimodipine Sustained Release Tablets Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Nimodipine Sustained Release Tablets Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Nimodipine Sustained Release Tablets Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Nimodipine Sustained Release Tablets Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Nimodipine Sustained Release Tablets Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Nimodipine Sustained Release Tablets Revenue by Region
7.1 Global Nimodipine Sustained Release Tablets Revenue by Region
7.1.1 Global Nimodipine Sustained Release Tablets Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Nimodipine Sustained Release Tablets Revenue by Region (2020-2025)
7.1.3 Global Nimodipine Sustained Release Tablets Revenue by Region (2026-2031)
7.1.4 Global Nimodipine Sustained Release Tablets Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Nimodipine Sustained Release Tablets Revenue (2020-2031)
7.2.2 North America Nimodipine Sustained Release Tablets Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Nimodipine Sustained Release Tablets Revenue (2020-2031)
7.3.2 Europe Nimodipine Sustained Release Tablets Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Nimodipine Sustained Release Tablets Revenue (2020-2031)
7.4.2 Asia-Pacific Nimodipine Sustained Release Tablets Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Nimodipine Sustained Release Tablets Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Nimodipine Sustained Release Tablets Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Arbor Pharmaceuticals
8.1.1 Arbor Pharmaceuticals Comapny Information
8.1.2 Arbor Pharmaceuticals Business Overview
8.1.3 Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Arbor Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
8.1.5 Arbor Pharmaceuticals Recent Developments
8.2 Bayer Vital
8.2.1 Bayer Vital Comapny Information
8.2.2 Bayer Vital Business Overview
8.2.3 Bayer Vital Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Bayer Vital Nimodipine Sustained Release Tablets Product Portfolio
8.2.5 Bayer Vital Recent Developments
8.3 Bionpharma
8.3.1 Bionpharma Comapny Information
8.3.2 Bionpharma Business Overview
8.3.3 Bionpharma Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Bionpharma Nimodipine Sustained Release Tablets Product Portfolio
8.3.5 Bionpharma Recent Developments
8.4 Heritage Pharmaceuticals
8.4.1 Heritage Pharmaceuticals Comapny Information
8.4.2 Heritage Pharmaceuticals Business Overview
8.4.3 Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Heritage Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
8.4.5 Heritage Pharmaceuticals Recent Developments
8.5 Pharmaceutics International
8.5.1 Pharmaceutics International Comapny Information
8.5.2 Pharmaceutics International Business Overview
8.5.3 Pharmaceutics International Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Pharmaceutics International Nimodipine Sustained Release Tablets Product Portfolio
8.5.5 Pharmaceutics International Recent Developments
8.6 Sofgen Pharmaceuticals
8.6.1 Sofgen Pharmaceuticals Comapny Information
8.6.2 Sofgen Pharmaceuticals Business Overview
8.6.3 Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Sofgen Pharmaceuticals Nimodipine Sustained Release Tablets Product Portfolio
8.6.5 Sofgen Pharmaceuticals Recent Developments
8.7 Wuhan HITECK Biopharmaceutical
8.7.1 Wuhan HITECK Biopharmaceutical Comapny Information
8.7.2 Wuhan HITECK Biopharmaceutical Business Overview
8.7.3 Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Wuhan HITECK Biopharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
8.7.5 Wuhan HITECK Biopharmaceutical Recent Developments
8.8 Sihuan Pharmaceutical
8.8.1 Sihuan Pharmaceutical Comapny Information
8.8.2 Sihuan Pharmaceutical Business Overview
8.8.3 Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Sihuan Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
8.8.5 Sihuan Pharmaceutical Recent Developments
8.9 Jiangsu Kanion Pharmaceutical
8.9.1 Jiangsu Kanion Pharmaceutical Comapny Information
8.9.2 Jiangsu Kanion Pharmaceutical Business Overview
8.9.3 Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Jiangsu Kanion Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
8.9.5 Jiangsu Kanion Pharmaceutical Recent Developments
8.10 Qilu Pharmaceutical
8.10.1 Qilu Pharmaceutical Comapny Information
8.10.2 Qilu Pharmaceutical Business Overview
8.10.3 Qilu Pharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Qilu Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
8.10.5 Qilu Pharmaceutical Recent Developments
8.11 Shandong Yunmen Pharmaceutical
8.11.1 Shandong Yunmen Pharmaceutical Comapny Information
8.11.2 Shandong Yunmen Pharmaceutical Business Overview
8.11.3 Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Shandong Yunmen Pharmaceutical Nimodipine Sustained Release Tablets Product Portfolio
8.11.5 Shandong Yunmen Pharmaceutical Recent Developments
8.12 Yabao Pharmaceutical Group
8.12.1 Yabao Pharmaceutical Group Comapny Information
8.12.2 Yabao Pharmaceutical Group Business Overview
8.12.3 Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Yabao Pharmaceutical Group Nimodipine Sustained Release Tablets Product Portfolio
8.12.5 Yabao Pharmaceutical Group Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Nimodipine Sustained Release Tablets Value Chain Analysis
9.1.1 Nimodipine Sustained Release Tablets Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Nimodipine Sustained Release Tablets Production Mode & Process
9.2 Nimodipine Sustained Release Tablets Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Nimodipine Sustained Release Tablets Distributors
9.2.3 Nimodipine Sustained Release Tablets Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.